The Relative Strength (RS) Rating for TransMedics Group headed into a higher percentile Thursday, as it got a lift from 69 to 73.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 as they launch their largest climbs. See if TransMedics Group can continue to rebound and clear that threshold.
TransMedics Group has risen more than 5% past an 85.51 entry in a third-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
While the company's top line growth fell last quarter from 64% to 50%, the bottom line grew 58%, up from 0% in the previous report. The next quarterly numbers are expected on or around May 8.
The company holds the No. 13 rank among its peers in the Medical-Products industry group. Boston Scientific, Penumbra and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
